Ontogenesis of Corydalis intermedia (l.) Merat in the “Bitsevsky forest” natural and historical park by M E Pavlova, I I Istomina, A A Terechin

Get full text

Herbicide hormesis to segregate a weed population? – A case study with Tripleurospermum perforatum (Mérat) Lainz by Belz, Regina G., Sinkkonen, Aki

“…In a dose-response experiment, Tripleurospermum perforatum (Mérat) Lainz was exposed to 12 doses of Atlantis WG (mesosulfuron + iodosulfuron) in 24 replicates (50 plants/replicate). …”
Get full text

P71 Treatment patterns, healthcare resource utilization and related costs of patients with discoid lupus erythematosus (DLE) or subacute cutaneous lupus erythematosus (SCLE) in the United States: a cohort study in the Merative™ MarketScan® database by Ying Sun, Benjamin F Chong, Caroline Foch, Sanjeev Roy, Dominika Weinelt, Sabrina de Souza, Xiaoxue Chen, Jeffrey M Muir

The analysis of AllameMajlesi’s comprehending way(Fighh al Hadith)in his commentary on al-Kaafi by Zohreh Bana Ahmadi Milani, Nahla Gharavi Naeeni, Elham Zarin-kolah

Subjects: Get full text

Kompleksna jezikovna identiteta kot posledica migracije v literarnih delih Brine Svit in Eve Hoffman by Megi Rožič

Subjects: “…brina švigelj merat (brina svit)…”
Get full text

analyzing and critiquing of fatuni's view about the possibility of interpreting of Qur'an by non-imam person by amir mahmudi, AliAhmad Naseh, Mohammad Ali Tajari

Subjects: Get full text

P1463: HEALTHCARE RESOURCE USE, ECONOMIC BURDEN AND IN-PATIENT MORTALITY IN PATIENTS WITH ALPHA- AND BETA-THALASSEMIA COMPARED TO MATCHED CONTROLS IN THE REAL-WORLD SETTING by Arielle L. Langer, Louise Lombard, Amey Rane, Keely Gilroy, Junlong LI, Jing Zhao, Carolyn Lew, Erin Bullock, Brian Davis, Sujit Sheth

Get full text

Risk factors for severe COVID-19 among patients with systemic lupus erythematosus: a real-world analysis of a large representative US administrative claims database, 2020–2021 by Cassandra Calabrese, Gelareh Atefi, Kristin A Evans, Meghan Moynihan, Liisa Palmer, Sze-Jung Wu

“…Objectives To identify risk factors for progression to severe COVID-19 and estimate the odds of severe COVID-19 associated with vaccination among patients with systemic lupus erythematosus (SLE).Methods This retrospective cohort study identified adults with SLE in the Merative™ MarketScan® Databases. Patients were continuously enrolled the year before 1 April 2020 (baseline) and had a COVID-19 diagnosis between 1 April 2020 and the earliest of death, enrolment end or 31 December 2021. …”
Get full text

RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020 by Elizabeth R. Packnett, Isabelle H. Winer, Heather Larkin, Abiola Oladapo, Tara Gonzales, Matthew Wojdyla, Mitchell Goldstein, Vincent C. Smith

Get full text

Work Loss and Direct and Indirect Costs Associated with Parkinson&rsquo;s Disease by Jerry M, Arcona S, McMorrow D, Schwartz H, Princic N, Sasane R

“…Michelle Jerry,1 Steve Arcona,2 Donna McMorrow,1 Hana Schwartz,1 Nicole Princic,1 Rahul Sasane2 1Merative, Ann Arbor, MI, USA; 2Cerevel Therapeutics, Cambridge, MA, USACorrespondence: Michelle Jerry, Merative, 100 Phoenix Dr Ste 200, Ann Arbor, MI, 48108, USA, Email michelle.jerry@merative.comPurpose: To examine work loss and indirect costs during the three-year periods prior to and following initial diagnosis of Parkinson’s disease (PD) in patients and in spouses of PD patients, as well as direct costs of healthcare.Patients and Methods: This is a retrospective, observational cohort study using the MarketScan Commercial and Health and Productivity Management databases.Results: A total of 286 employed PD patients and 153 employed spouses met all diagnostic and enrollment criteria for short-term disability (STD) analysis (PD Patient cohort and Caregiving Spouse cohort). …”
Get full text

Observational cohort investigating health outcomes and healthcare costs after metabolic and bariatric surgery: a study protocol by Feibi Zheng, Elizabeth Wall-Wieler, Victoria Gershuni, Yuki Liu, Maria S Altieri

“…Baseline demographics, health outcomes, and costs will be examined in the year before the index date, remission and new-onset comorbidities, and healthcare costs will be examined at 1 and 3 years after the index date.Ethics and dissemination As this was an observational study of deidentified patients in the Merative database, Institutional Review Board approval and consent were exempt (in accordance with the Health Insurance Portability and Accountability Act Privacy Rule). …”
Get full text

Risk of RSV-related hospitalization is associated with gestational age in preterm (born at 29–34 wGA) infants without outpatient palivizumab administration by Elizabeth R. Packnett, Isabelle H. Winer, Abiola Oladapo, Matthew Wojdyla

Get full text

Biologic use and treatment patterns in patients with chronic rhinosinusitis with nasal polyps: a US real-world study by Jared Silver, Elizabeth Packnett, Julie Park, Arijita Deb

“…Methods Adults in the Merative MarketScan Commercial and Medicare Supplemental Databases with medical claims for CRSwNP were identified June 2018–June 2019 (identification period [IP]). …”
Get full text

Meningococcal serogroup B vaccination series initiation in the United States: A real-world claims data analysis by Elizabeth R. Packnett, Nicole M. Zimmerman, Patricia Novy, Laura C. Morgan, Nnenna Chime, Parinaz Ghaswalla

Get full text

Neonatal Drug Formularies—A Global Scope by Dotan Shaniv, Srinivas Bolisetty, Thomas E. Young, Barry Mangum, Sean Ainsworth, Linda Elbers, Petra Schultz, Melanie Cucchi, Saskia N. de Wildt, Tjitske M. van der Zanden, Neil Caldwell, Anne Smits, Karel Allegaert

Get full text

A real-world analysis of hybrid CDA and ACDF compared to multilevel ACDF by Kee D Kim, Domagoj Coric, Armen Khachatryan, Brenna L Brady, Timothy Lillehaugen, Mike McCormack, William B Dolman, Richard Ditto

Get full text

Impact of Elexacaftor/Tezacaftor/Ivacaftor on Healthcare Resource Utilization and Associated Costs Among People With Cystic Fibrosis in the US: A Retrospective Claims Analysis by Michael S. Schechter, Natalia Sabater-Anaya, Gerry Oster, Derek Weycker, Hongsheng Wu, Emilio Arteaga-Solis, Sukirti Bagal, Lisa J. McGarry, Kate Van Brunt, Jessica Morlando Geiger

“…Methods We evaluated the rates of PEx, HCRU, and associated costs before and after initiation of ELX/TEZ/IVA in people with CF aged ≥ 12 years using data from the Merative MarketScan® Commercial Claims and Encounters Database and the Merative Multi-State Medicaid Database from April 21, 2019 to December 31, 2020. …”
Get full text

A Comparative Analysis of Three Online Drug-Drug Interaction Checkers: A Short Communication by Diego Rodrigues de Aguilar, Alex Junio Silva Cruz, Maria Auxiliadora Parreiras Martins, Mauro Henrique Nogueira Guimarães Abreu

“…The occurrence of DDI was determined by entering the name of the drugs taken by each patient into Merative Micromedex®, Medscape®, and DrugBank. The degree of agreement among the three DDI online checkers was analyzed using the Fleiss' kappa test. …”
Get full text

Comparison of Treatment Patterns in Patients with Migraine Initiating Calcitonin Gene-Related Peptide Monoclonal Antibodies: A Retrospective Real-World US Study by Varnado OJ, Brady BL, Zagar AJ, Robles YP, Hoyt M

“…Oralee J Varnado,1 Brenna L Brady,2 Anthony J Zagar,1 Yvonne P Robles,2 Margaret Hoyt1 1Eli Lilly and Company, Indianapolis, IN, USA; 2Merative, Ann Arbor, MI, USACorrespondence: Oralee J VarnadoValue, Evidence, and Outcomes, Eli Lilly and Company, Lilly Corporate Center, 893 Delaware Street, Indianapolis, IN, 46285, USA, Tel +1 317 277 0599, Email varnado_oralee_johnson@lilly.comBackground: Calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) are indicated for migraine prevention in the United States. …”
Get full text

Real-world treatment patterns and healthcare costs in patients with psoriasis taking systemic oral or biologic therapies by Sydney Thai, Joe Zhuo, Yichen Zhong, Qian Xia, Xiu Chen, Ying Bao, Devender Dhanda, Lawshia Priya, Jashin J. Wu

“…Methods This retrospective cohort study used IBM® (now Merative™) MarketScan® Commercial and Medicare claims (1 January 2006–31 December 2019) to evaluate patterns of switching, discontinuation, and nonswitching in two cohorts of patients initiating oral or biologic systemic therapy. …”
Get full text